Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORTNASDAQ:DNAANASDAQ:PLSENASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$29.82+0.4%$25.52$21.97▼$32.33$1.28B1.54327,065 shs47,245 shsDNAASocial Capital Suvretta Holdings Corp. I$14.07$11.74$9.07▼$17.44$360.76M-0.02182,488 shs4.63 million shsPLSEPulse Biosciences$17.60-1.4%$16.71$9.70▼$25.00$1.18B1.6191,206 shs19,877 shsTNDMTandem Diabetes Care$20.70-2.7%$19.44$15.75▼$53.69$1.38B1.471.55 million shs266,253 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+0.24%+4.88%+24.33%+17.56%+25.35%DNAASocial Capital Suvretta Holdings Corp. I0.00%0.00%0.00%0.00%0.00%PLSEPulse Biosciences-0.50%+5.81%+0.22%-2.57%+41.36%TNDMTandem Diabetes Care+0.61%+3.10%+26.89%-3.88%-58.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORTArtivion1.4474 of 5 stars1.61.00.00.02.72.51.9DNAASocial Capital Suvretta Holdings Corp. IN/AN/AN/AN/AN/AN/AN/AN/APLSEPulse Biosciences0.7932 of 5 stars0.00.00.04.21.63.30.0TNDMTandem Diabetes Care4.3078 of 5 stars4.21.00.04.92.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 3.17Buy$31.405.32% UpsideDNAASocial Capital Suvretta Holdings Corp. I 0.00N/AN/AN/APLSEPulse Biosciences 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.47Hold$35.8673.22% UpsideCurrent Analyst Ratings BreakdownLatest DNAA, TNDM, AORT, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/6/2025AORTArtivionCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025AORTArtivionJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.005/6/2025AORTArtivionNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.005/1/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.005/1/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.005/1/2025TNDMTandem Diabetes CareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.004/10/2025TNDMTandem Diabetes CareMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$20.004/9/2025TNDMTandem Diabetes CareMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$390.08M3.26$0.81 per share36.78$6.87 per share4.34DNAASocial Capital Suvretta Holdings Corp. IN/AN/AN/AN/A($0.33) per shareN/APLSEPulse Biosciences$700K1,690.98N/AN/A$0.81 per share21.72TNDMTandem Diabetes Care$982.95M1.40N/AN/A$4.81 per share4.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion-$30.69M-$0.50N/A59.63N/A-0.22%5.15%1.91%8/14/2025 (Estimated)DNAASocial Capital Suvretta Holdings Corp. I-$2.44MN/A0.00∞N/AN/AN/A-3.32%N/APLSEPulse Biosciences-$42.21MN/A0.00∞N/AN/A-96.89%-74.83%8/11/2025 (Estimated)TNDMTandem Diabetes Care-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%8/7/2025 (Estimated)Latest DNAA, TNDM, AORT, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A5/5/2025Q1 2025AORTArtivion$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ADNAASocial Capital Suvretta Holdings Corp. IN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion0.711.881.33DNAASocial Capital Suvretta Holdings Corp. IN/A0.090.09PLSEPulse BiosciencesN/A11.9311.93TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%DNAASocial Capital Suvretta Holdings Corp. IN/APLSEPulse Biosciences76.95%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAORTArtivion7.60%DNAASocial Capital Suvretta Holdings Corp. IN/APLSEPulse Biosciences71.50%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,30042.70 million38.52 millionOptionableDNAASocial Capital Suvretta Holdings Corp. I425.64 millionN/ANot OptionablePLSEPulse Biosciences14067.27 million17.53 millionOptionableTNDMTandem Diabetes Care2,60066.61 million64.23 millionOptionableDNAA, TNDM, AORT, and PLSE HeadlinesRecent News About These CompaniesTandem agrees to pay $36M to settle Roche patent litigationMay 29 at 2:01 PM | drugdeliverybusiness.comReflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)May 28 at 12:09 AM | msn.comNuveen Asset Management LLC Grows Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 26, 2025 | marketbeat.comJanus Henderson Group PLC Has $1.07 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 26, 2025 | marketbeat.comTandem Diabetes and Roche Reach a Patent SettlementMay 26, 2025 | msn.comTandem Diabetes and Roche Reach a Patent SettlementMay 25, 2025 | insidermonkey.comDeutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 25, 2025 | marketbeat.comBank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 25, 2025 | marketbeat.comQuantinno Capital Management LP Has $1.86 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 24, 2025 | marketbeat.comBNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 24, 2025 | marketbeat.comTandem Diabetes Agrees to Pay Roche $36M in Patent Infringement DealMay 23, 2025 | marketwatch.comTandem Diabetes Care (TNDM) Settles Patent Dispute with RocheMay 23, 2025 | gurufocus.comConnective Capital Management LLC Purchases New Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 23, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Two Sigma Advisers LPMay 23, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Acquired by Two Sigma Investments LPMay 23, 2025 | marketbeat.comShould Tandem Diabetes Stock Stay in Your Portfolio Now?May 22, 2025 | zacks.comAmeriprise Financial Inc. Sells 525,159 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 21, 2025 | marketbeat.comTandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technologyMay 20, 2025 | drugdeliverybusiness.comSilvercrest Asset Management Group LLC Purchases 78,347 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys 254,605 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 20, 2025 | marketbeat.comJefferies Financial Group Inc. Has $330,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNAA, TNDM, AORT, and PLSE Company DescriptionsArtivion NYSE:AORT$29.82 +0.11 (+0.35%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Social Capital Suvretta Holdings Corp. I NASDAQ:DNAASocial Capital Suvretta Holdings Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology industry. The company was incorporated in 2021 and is based in Henderson, Nevada.Pulse Biosciences NASDAQ:PLSE$17.60 -0.25 (-1.37%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Tandem Diabetes Care NASDAQ:TNDM$20.70 -0.58 (-2.73%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
